ArticleIrish journal of medical science2026
Should we use the SARC-F score in sarcopenia screening in kidney transplant patients?
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe risk of sarcopenia is increased in kidney transplant (KT) patients. The SARC-F score is a reliable tool used for sarcopenia screening; however, it has not been tested in KT patients.
objectiveThe aim of our study is to assess the prevalence of sarcopenia in KT recipients and to investigate the relationship between the SARC-F score and sarcopenia parameters.
methodsThe study included 150 KT patients. Body muscle mass was measured using the Tanita DC 360 ST device. Before these measurements, patients were scored using the five-question SARC-F assessment, and their scores were recorded.
results28 patients were diagnosed with sarcopenia, yielding a sarcopenia prevalence of 18.7%. The mean age of the patients was 42.1 ± 13.5 years. Correlation analysis of SARC-F scoring results revealed a negative correlation between SARC-F and total muscle mass, muscle percentage, skeletal muscle mass, skeletal muscle index, grip strength, and walking speed parameters, as expected. Analysis of SARC-F scores showed that only 12 of the 150 patients had a SARC-F score greater than 4. Patients with a SARC-F score ≥ 4 had lower muscle percentage, total muscle mass, skeletal muscle mass, handgrip strength, and walking speed than those with a score < 4. However, only one of these patients met the criteria for sarcopenia.
conclusionThe findings of this study indicate that the SARC-F score is associated with muscle mass and strength parameters in KT patients and may be used as a screening tool. However, it is not sufficient as a standalone diagnostic tool for sarcopenia.
Indexed as
Identifiers
42799982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.